PET/MRI Study on Changes of Fat and Muscle Metabolism.

Study Overview
=================
Brief Summary
-----------------
False positives for Brown Fat & Muscle（F&M） always affect the evaluation of metabolic disease treatment. Recently, using PET/CT，international journals such as Journal of Nuclear Medicine reported that the amount of active brown fat was correlated with renal creatinine clearance and subject to regulation by atrial natriuretic peptide in addition to association of season and temperature. At present，studies based on PET/CT have shown that elimination of the above factors, brown fat(even muscle) will still appear false positive metabolism in tumor patients. In view of the basis of Positron emission computed tomography/Magnetic resonance (PET/MRI) brain function research，our team speculate that it may be related to psychological or cortex metabolism. And there is a lack of studies on the correlation between the psychosocial，cortex structure and metabolism. Therefore, it suggests that，combination of structure and metabolism，PET/MRI will play a role in studying the effects of psychological on F&M false-positive metabolism in malignant patients. In this project, the investigators intend to observe the changes of F&M metabolism with psychological and cortex metabolism after comprehensive treatment in malignant patient by combining PET/MRI. The relationship between F&M metabolism and psychological will be deeply analyzed to provide scientific basis for the development of the differential diagnosis and assessment.

Official Title
-----------------
PET/MRI Study on the Effects of Psychosocial on Fat and Muscle Metabolism for Malignant Tumor Patient After Comprehensive Treatment.

Conditions
-----------------
Brown Fat and Muscle Metabolic, Differential Diagnosis

Intervention / Treatment
-----------------
* Other: Comprehensive treatment of tumor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of malignant tumor Have not yet been receiving comprehensive treatment and should begin within one month Fasting glucose of diabetic patients is controlled below 11.1 mmol/L. Inclusion Criteria for Healthy Control Participants: • Clinical diagnosis of Healthy Control Exclusion Criteria: Fasting glucose ≥11.1mmol/L History of endocrine disease (such as chronic glomerulonephritis, Addison's disease) Neurological signs and/or history of neurological disease Have begun comprehensive treatment Presence of magnetically active objects in the body Claustrophobia or any other medical condition that would preclude the participant from lying in the PET/MRI scanner for approximately 40 mins.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observation group of positive F&M<br>The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year | Other: Comprehensive treatment of tumor<br>* According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.<br>|
| Observation group of no abnormal changes in F&M<br>The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year | Other: Comprehensive treatment of tumor<br>* According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.<br>|
| The control group<br>Corresponding to the observation group, the time, sequence and protocol were consistent | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change metabolism of glucose of M&F | Glucose metabolic scores will be assessed with visual scale | Baseline, 1 day ( Contrast scanning) | 
| Change of the glucose metabolism area of M&F | Five different anatomical locations (subphrenic, paravertebral, mediastinal, cervical, supraclavicular) will be assessed with visual. | Baseline, 1 day ( Contrast scanning) | 
| Change of activated M&F volume | Activated M&F volume before and after comprehensive treatment were evaluated by post-processing software | Baseline, 1 day ( Contrast scanning) | 
| Change of M&F SUVmax and SUVmean | SUVmax and SUVmean scores will be measured by post-processing software. | Baseline, 1 day ( Contrast scanning) | 
| Change of anxiety symptoms | Anxiety symptoms scores will be assessed with Hamilton Anxiety Scale. | Baseline, 1 day ( Contrast scanning) | 
| Change of sleep | Sleep scores will be assessed with Pittsburgh sleep quality index one month before scanning | Baseline, 1 day ( Contrast scanning) | 
| Change of metabolism of glucose in the M&F | Accumulation of 18F-FDG will be analyzed by treatment-related, psychology-related and intervention-related Positron emission tomography/ Magnetic resonance | Baseline, 1 day ( Contrast scanning) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psychological, Comprehensive treatment, Positron emission computed tomography/Magnetic resonance